本文采用MTT法,观察不同浓度辛伐他汀(0,1,3,10,30 and 100μmol/L)对C2C12细胞活力的影响,并通过定量RT-PCR方法对utrophin和TNF-α基因的mRNA的表达进行了研究.随着辛伐他汀浓度和作用时间的增加,C2C12细胞的活力在降低;不同浓度辛伐...本文采用MTT法,观察不同浓度辛伐他汀(0,1,3,10,30 and 100μmol/L)对C2C12细胞活力的影响,并通过定量RT-PCR方法对utrophin和TNF-α基因的mRNA的表达进行了研究.随着辛伐他汀浓度和作用时间的增加,C2C12细胞的活力在降低;不同浓度辛伐他汀对utrophin和TNF-α的mRNA表达具有影响作用,为阐明辛伐他汀的肌毒性作用机理提供了新的思路.展开更多
Duchenne muscular dystrophy(DMD)is a serious genetic neuromuscular rare disease that is prevalent and caused by the mutation/deletion of the X-linked DMD gene that encodes dystrophin.Utrophin is a dystrophin homologou...Duchenne muscular dystrophy(DMD)is a serious genetic neuromuscular rare disease that is prevalent and caused by the mutation/deletion of the X-linked DMD gene that encodes dystrophin.Utrophin is a dystrophin homologous protein on human chromosome 6.Dystrophin and utrophin are highly homologous.They can recruit many dystrophin-glycoprotein complex(DGC)-related proteins and co-localize at the sarcolemma in the early stage of human embryonic development.Moreover,utrophin is overexpressed naturally at the mature myofiber sarcolemma in DMD patients.Therefore,utrophin is considered the most promising homologous protein to replace dystrophin.This review summarizes various modulating drugs and gene therapy approaches for utrophin replacement.As a universal method to treat DMD disease,utrophin has a promising therapeutic prospect and deserves further investigation.展开更多
文摘本文采用MTT法,观察不同浓度辛伐他汀(0,1,3,10,30 and 100μmol/L)对C2C12细胞活力的影响,并通过定量RT-PCR方法对utrophin和TNF-α基因的mRNA的表达进行了研究.随着辛伐他汀浓度和作用时间的增加,C2C12细胞的活力在降低;不同浓度辛伐他汀对utrophin和TNF-α的mRNA表达具有影响作用,为阐明辛伐他汀的肌毒性作用机理提供了新的思路.
基金the National Natural Science Foundation of China(81930121,82125008)the National Key Research and Development Program of China(2018YFA0801403,2018YFA0107902)the Major Basic Research Project of Science and Technology of Yunnan(202001BC070001,202105AC160041).
文摘Duchenne muscular dystrophy(DMD)is a serious genetic neuromuscular rare disease that is prevalent and caused by the mutation/deletion of the X-linked DMD gene that encodes dystrophin.Utrophin is a dystrophin homologous protein on human chromosome 6.Dystrophin and utrophin are highly homologous.They can recruit many dystrophin-glycoprotein complex(DGC)-related proteins and co-localize at the sarcolemma in the early stage of human embryonic development.Moreover,utrophin is overexpressed naturally at the mature myofiber sarcolemma in DMD patients.Therefore,utrophin is considered the most promising homologous protein to replace dystrophin.This review summarizes various modulating drugs and gene therapy approaches for utrophin replacement.As a universal method to treat DMD disease,utrophin has a promising therapeutic prospect and deserves further investigation.
